JP2022519019A5 - - Google Patents

Info

Publication number
JP2022519019A5
JP2022519019A5 JP2021541152A JP2021541152A JP2022519019A5 JP 2022519019 A5 JP2022519019 A5 JP 2022519019A5 JP 2021541152 A JP2021541152 A JP 2021541152A JP 2021541152 A JP2021541152 A JP 2021541152A JP 2022519019 A5 JP2022519019 A5 JP 2022519019A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
smg
smu
sm5c
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519019A (ja
JP7661228B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015971 external-priority patent/WO2020160336A1/en
Publication of JP2022519019A publication Critical patent/JP2022519019A/ja
Publication of JP2022519019A5 publication Critical patent/JP2022519019A5/ja
Priority to JP2025060960A priority Critical patent/JP2025107175A/ja
Application granted granted Critical
Publication of JP7661228B2 publication Critical patent/JP7661228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541152A 2019-02-01 2020-01-30 オリゴヌクレオチド組成物及びその方法 Active JP7661228B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060960A JP2025107175A (ja) 2019-02-01 2025-04-02 オリゴヌクレオチド組成物及びその方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962800409P 2019-02-01 2019-02-01
US62/800,409 2019-02-01
US201962911335P 2019-10-06 2019-10-06
US62/911,335 2019-10-06
PCT/US2020/015971 WO2020160336A1 (en) 2019-02-01 2020-01-30 Oligonucleotide compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060960A Division JP2025107175A (ja) 2019-02-01 2025-04-02 オリゴヌクレオチド組成物及びその方法

Publications (3)

Publication Number Publication Date
JP2022519019A JP2022519019A (ja) 2022-03-18
JP2022519019A5 true JP2022519019A5 (enExample) 2023-02-08
JP7661228B2 JP7661228B2 (ja) 2025-04-14

Family

ID=71840465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541152A Active JP7661228B2 (ja) 2019-02-01 2020-01-30 オリゴヌクレオチド組成物及びその方法
JP2025060960A Pending JP2025107175A (ja) 2019-02-01 2025-04-02 オリゴヌクレオチド組成物及びその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060960A Pending JP2025107175A (ja) 2019-02-01 2025-04-02 オリゴヌクレオチド組成物及びその方法

Country Status (14)

Country Link
US (1) US20220098585A1 (enExample)
EP (1) EP3917497A4 (enExample)
JP (2) JP7661228B2 (enExample)
KR (1) KR20210121199A (enExample)
CN (1) CN113423385A (enExample)
AU (2) AU2020216186C1 (enExample)
BR (1) BR112021014940A2 (enExample)
CA (1) CA3126845A1 (enExample)
IL (1) IL284882A (enExample)
MA (1) MA54875A (enExample)
MX (1) MX2021009178A (enExample)
SG (1) SG11202107318YA (enExample)
TW (2) TW202526020A (enExample)
WO (1) WO2020160336A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
FR3121039B1 (fr) * 2021-03-25 2023-03-31 Univ Grenoble Alpes Oligonucléotides anti-sens pour leur utilisation dans un traitement anticancéreux
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
EP4423272A2 (en) * 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4569115A4 (en) * 2022-08-11 2026-07-15 Wave Life Sciences Ltd OLIGONUCLEOTID COMPOSITIONS AND ASSOCIATED PROCESSES
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4753719A1 (en) * 2023-08-03 2026-06-10 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507836A (ja) * 1993-11-16 1997-08-12 ジンタ・インコーポレイテッド 非ホスホネート・ヌクレオシジル間結合と混合したキラリティー的に純粋なホスホネート・ヌクレオシジル間結合を有する合成オリゴマー
US8987222B2 (en) * 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
JP6018506B2 (ja) * 2010-02-08 2016-11-02 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
US20140303235A1 (en) * 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
EP4086347A3 (en) * 2012-10-12 2023-01-11 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
CN117965536A (zh) * 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP3452596A4 (en) * 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
AU2018316159A1 (en) * 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Similar Documents

Publication Publication Date Title
JP2025165976A5 (enExample)
JP2021074021A5 (enExample)
JP2025041652A5 (enExample)
JP7348922B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
EP3324978A1 (en) Oligonucleotide compositions and methods thereof
JP2019534009A5 (enExample)
JP2022513719A5 (enExample)
WO2018067973A1 (en) Oligonucleotide compositions and methods thereof
JP2022532169A5 (enExample)
JP2022527105A5 (enExample)
JP2016530882A5 (enExample)
BR112020018902A2 (pt) oligonucleotídeo antissenso com toxicidade reduzida
JP2018525357A5 (enExample)
JPH05505101A (ja) オリゴヌクレオチド療法における三重らせん形成
JP2021502095A5 (enExample)
FR2931824A1 (fr) Procede de synthese d'arn par voie chimique.
JP2022524435A5 (enExample)
BR112020010090A2 (pt) oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos
JP2021511072A5 (enExample)
JP2024541771A5 (enExample)
JP2023543215A5 (enExample)
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
JP2025511183A5 (enExample)
JP2025518487A5 (enExample)